Pearl Bio, Inc.
Cambridge, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 700 Main St, Cambridge, MA 02139, USA
- Website
- pearlbio.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $249,967 |
| FY2025 | $850,398 |
| FY2024 | $849,580 |
| FY2023 | $249,998 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Office of the Secretary of Defense | $249,967 |
Contract awards
Grant awards
Similar vendors
About the company
Pearl Bio, Inc., a synthetic biology and biomanufacturing research firm based in Cambridge, Massachusetts, operates as a prime recipient on federal grants and small-business research contracts focused on engineering sequence-defined biopolymers and next-generation protein biologics using genomically recoded organisms and non-canonical amino acids. The company competes exclusively under the Total Small Business set-aside category across both contract and grant vehicles.
Pearl Bio's capability portfolio centers on synthetic biology platform development and scalable biomanufacturing. Its recent contract work includes two Army RDECOM STTR Phase projects: a Phase II Definitive Contract valued at $1.7 million awarded May 23, 2024 (completing May 31, 2026) for scalable production of sequence-defined biopolymers containing multiple distinct non-canonical amino acids in recoded cell and cell-free systems, and a Phase I purchase order valued at $249,967.35 awarded April 1, 2026 (completing March 31, 2027) to engineer and repurpose the translation apparatus in genomically recoded organisms to produce aramid-containing copolymers. Pearl Bio also holds an Office of the Secretary of Defense STTR Phase I purchase order valued at $249,998.00 (awarded March 1, 2023, completed February 29, 2024) on the same biopolymer platform.
On the grant side, Pearl Bio is a recipient of two National Institute of General Medical Sciences project grants from the Department of Health and Human Services: one focused on development of programmable nanobodies for multifunctionalized biologics (awarded June 1, 2024, completing November 30, 2024) and another on next-generation biologics programmed with multifunctional synthetic chemistries (awarded March 1, 2024, completing August 31, 2025). The National Science Foundation awarded Pearl Bio a $274,462 SBIR Phase I project grant under the Technology, Innovation, and Partnerships program (CFDA 47.084) in August 2023 for a consolidated platform to engineer and produce novel biopolymers.
Customer concentration divides evenly between defense research and health-sciences grants. The Army RDECOM and the Department of Defense account for $1.9 million in contract value across two awards, while the National Institute of General Medical Sciences carries two grants of undisclosed value. The National Science Foundation rounds out the customer set with one grant. The vendor faces one recompete exposure in the next twenty-four months: the Army Phase I purchase order valued at $250 thousand completing March 31, 2027. All six awards are prime-position, grant or STTR contract work; Pearl Bio carries no subcontract footprint in the source data.
Quick answers
Is Pearl Bio, Inc. registered in SAM.gov?
Yes. Pearl Bio, Inc.'s SAM.gov registration is active through December 18, 2026.
What is Pearl Bio, Inc.'s CAGE code?
Pearl Bio, Inc.'s CAGE code is 9B0A4, and its Unique Entity ID (UEI) is QRR3ELYYB486.
How much has Pearl Bio, Inc. received in federal contracts?
Federal contracts obligated $850,398 to Pearl Bio, Inc. in fiscal year 2025 and $2,199,943 in fiscal years 2023 through 2027.
What is Pearl Bio, Inc.'s most recent federal award?
Pearl Bio, Inc.'s most recent federal contract award is Small business technology transfer research (STTR) services phase I effort titled scalable production of… (W911NF26PA006), from ACC Aberdeen Proving Ground, on April 1, 2026.
On GovTribe
See Pearl Bio, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors